Immunotherapy Study for Patients With Stage IV Melanoma
Status:
Active, not recruiting
Trial end date:
2033-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors
(drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination
with the experimental immunotherapy drug, dorgenmeltucel-L, for melanoma. We hypothesize that
this form of combinatorial immunotherapy will result in tumor stabilization or shrinkage,
significant prolongation of progression-free, disease-free or overall survival compared to
the use of immune checkpoint inhibitors alone.